Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–62.
Article
CAS
PubMed
Google Scholar
Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol. 2020;15(4):499–519.
Article
CAS
PubMed
Google Scholar
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–72.
Article
CAS
PubMed
Google Scholar
Petitprez F, Meylan M, de Reyniès A, Sautès-Fridman C, Fridman WH. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou C, Liu Q, Xiang Y, Gou X, Li W. Role of the tumor immune microenvironment in tumor immunotherapy (Review). Oncol Lett. 2022;23(2):53.
Article
CAS
PubMed
Google Scholar
Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):72.
Article
PubMed
PubMed Central
Google Scholar
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.
Article
CAS
PubMed
Google Scholar
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57.
Article
CAS
PubMed
Google Scholar
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bianchini GD, Dugo M, Huang C, Egle D, Bermejo B, Seitz RS, Nielsen TJJ, Zamagni C, Thill M, Anton A, Russo S, Ciruelos EM, Schweitzer BL, Greil R, Semiglazov V, Gyorffy B, Valagussa P, Viale G, Callari M, Gianni L. Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial. Ann Oncol. 2021;32:S1283–346.
Article
Google Scholar
Dugo MH, Chiun-Sheng; Egle, Daniel; Berñejo, Bego a; Zamagni, Claudio; Seitz , Robert S.; Nielsen, Tyler J.; Thill, Marc; Anton, Antonio; Russo, Stefania; Ciruelos, Eva Maria; Schweitzer, Brock L.; Ross, Douglas T.; Galbardi, Barbara; Greil, Richard; Semiglazov, Vladimir; Gyorffy, Balazs; Colleoni, Marco; Kelly, Catherine; Mariani, Gabriella; Lucia Del Mastro; Valagussa, Pinuccia; Viale, Giuseppe; Callari, Maurizio; Gianni, Luca; Bianchini, Giampaolo. editor Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial. San Antonio Breast Cancer Symposium. San Antonio, Texas: AACR; 2021.
Iwase T, Blenman KRM, Li X, Reisenbichler E, Seitz R, Hout D, et al. A novel immunomodulatory 27-gene signature to predict response to neoadjuvant immunochemotherapy for primary triple-negative breast cancer. Cancers (Basel). 2021;13(19):4839.
Article
CAS
Google Scholar
Nielsen TJ, Ring BZ, Seitz RS, Hout DR, Schweitzer BL. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon. 2021;7(3):e06438.
Article
PubMed
PubMed Central
Google Scholar
Ranganath H, Jain AL, Smith JR, Ryder J, Chaudry A, Miller E, et al. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC Cancer. 2022;22(1):407.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11(6):e0157368.
Article
PubMed
PubMed Central
Google Scholar
Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, et al. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer. 2016;16:143.
Article
PubMed
PubMed Central
Google Scholar
Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, et al. Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy. JCO Precis Oncol. 2022;6:e2000368.
Article
PubMed
PubMed Central
Google Scholar
Seliger B, Massa C. Immune therapy resistance and immune escape of tumors. Cancers. 2021;13(3):551.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kannan A, Hertweck KL, Philley JV, Wells RB, Dasgupta S. Genetic mutation and exosome signature of human papilloma virus associated oropharyngeal cancer. Sci Rep. 2017;7:46102.
Article
CAS
PubMed
PubMed Central
Google Scholar
Romeo E, Caserta CA, Rumio C, Marcucci F. The vicious cross-talk between tumor cells with an EMT phenotype and cells of the immune system. Cells. 2019;8(5):460.
Article
CAS
PubMed Central
Google Scholar
Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.
Article
CAS
PubMed
Google Scholar
Chen XH, Liu ZC, Zhang G, Wei W, Wang XX, Wang H, et al. TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells. Mol Immunol. 2015;65(1):34–42.
Article
CAS
PubMed
Google Scholar
Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020.
Google Scholar
Team R. RStudio: integrated development environment for R. Boston: RStudio, PBC; 2021.
Google Scholar
Gu Z. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016. https://doi.org/10.1093/bioinformatics/btw313.
Article
PubMed
PubMed Central
Google Scholar
Morgan M, Davis Sean. Genomic Data Commons: NIH/NCI Genomic Data Commons Access. 2020.
Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.
Article
PubMed
Google Scholar
Mounir M, Lucchetta M, Silva TC, Olsen C, Bontempi G, Chen X, et al. New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput Biol. 2019;15(3):e1006701.
Article
PubMed
PubMed Central
Google Scholar
Silva TC, Colaprico A, Olsen C, D’Angelo F, Bontempi G, Ceccarelli M, et al. TCGA workflow: analyze cancer genomics and epigenomics data using Bioconductor packages. F1000Res. 2016;5:1542.
Article
PubMed
PubMed Central
Google Scholar
Nickles DB, Richard. IMvigor210corebiologies: data processing and analysis code for the manuscript Mariathasan et al, TGF-b attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells. R package version 0.1.13. 2018. http://research-pub.gene.com/IMvigor210CoreBiologies/IMvigor210CoreBiologies.tar.gz.
T T. A package for survival analysis in R_. 3.2–11 ed. 2021. https://cran.r-project.org/web/packages/survival/index.html.
Gerds TA. Prodlim: product-limit estimation for censored event history analysis. R package version. 2019. https://cran.r-project.org/web/packages/prodlim/index.html.
Venables WN, Ripley BD. Modern applied statistics with S. 4th ed. New York: Springer; 2002.
Book
Google Scholar
Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26(3):297–307.
Article
Google Scholar
Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017;242(1):113–25.
Article
PubMed
PubMed Central
Google Scholar
Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377–86.
Article
PubMed
Google Scholar
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.
Article
PubMed
PubMed Central
Google Scholar
Yoon J, Kim M, Posadas EM, Freedland SJ, Liu Y, Davicioni E, et al. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis. 2021;24(3):733–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3(12):1663–72.
Article
PubMed
PubMed Central
Google Scholar